Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Adicionar filtros








Intervalo de ano
1.
Pediatr. mod ; 48(7)jul. 2012.
Artigo em Português | LILACS | ID: lil-663138

RESUMO

Atualização dos principais aspectos relativos à nutrição na infância e adolescência, com particular enfoque nos principais distúrbios alimentares encontrados nessa faixa etária, anorexia nervosa e bulimia nervosa e abordando os recursos diagnósticos e a conduta terapêutica.


Assuntos
Humanos , Masculino , Feminino , Adolescente , Anorexia Nervosa/diagnóstico , Anorexia Nervosa/etnologia , Anorexia Nervosa/patologia , Anorexia Nervosa/terapia , Bulimia Nervosa/diagnóstico , Bulimia Nervosa/etnologia , Bulimia Nervosa/patologia , Bulimia Nervosa/terapia , Nutrição do Adolescente
2.
Pediatr. mod ; 38(8): 377-380, ago. 2002.
Artigo em Português | LILACS | ID: lil-504915
3.
Arq. bras. endocrinol. metab ; Arq. bras. endocrinol. metab;37(1): 31-3, mar. 1993. graf
Artigo em Inglês | LILACS | ID: lil-162703

RESUMO

The aim of this report was to determine the effect of fluoxetine on weight loss in a group of non depressed overweight subjects. The study was conducted for 12 weeks, and the patients were randomized for a double-blind, placebo controlled trial in the outpatient clinic of the University Hospital. Twenty patients (20-50 years old) were eligible because of BMI over 30 kg/m2, and free of other diseases including hypertension, diabetes mellitus or history of substance abuse. All patients were instructed to follow a standard hypocaloric diet, and to exercise regularly; they received either placebo or fluoxetine (20 mg twice daily after breakfast and lunch). A biochemical profile was obtained from all patients and repeated at 60 and 90 days. Fluoxetine-treated subjects (n = 10) lost weight than placebo treated subjects (n=8)(8.2 ñ 2.8 vs. 1.7ñ 1.3kg, p < 0.01) at 90 days of the trial. Also the body mass index (BMI) was significantly reduced in the fluoxetine treated group (35.1 ñ 5.1 to 31.7 ñ 5.2 kg/m2) but not in the placebo group. During active treatment, there was no significant changes in the serum biochemical profile in both groups. Side effects were minimal and similar in both groups. These results suggest that fluoxetine may be of benefit in the treatment of obese patients in whom standard dietary counseling has failed to produce weight loss.


Assuntos
Humanos , Pessoa de Meia-Idade , Adulto , Fluoxetina/uso terapêutico , Obesidade/tratamento farmacológico , Índice de Massa Corporal , Método Duplo-Cego
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA